ADCAN Pharma and Pinnacle Life Science agree licensing and technology-transfer deal for 12 oncology products
ADCAN Pharma and Pinnacle Life Science have entered into a licensing and technology-transfer partnership covering 12 oncology products and their planned local manufacture in the UAE.
The agreement combines product licensing with staged technology transfer intended to build local manufacturing capability for critical oncology medicines.
The partnership supports pharmaceutical localisation in the UAE while expanding ADCAN Pharma's oncology manufacturing portfolio.
Field | Content |
Alert Type | Deal |
Companies | ADCAN Pharma; Pinnacle Life Science |
Deal Type | Licensing and technology-transfer agreement |
Assets | 12 oncology products |
Therapy Area(s) | Oncology |
Geography | United Arab Emirates |
Deal Value | Financial terms were not disclosed |
What Happened | ADCAN Pharma and Pinnacle Life Science entered into an agreement covering the licensing of 12 oncology products and staged transfer of manufacturing technology to the UAE. |
Why It Matters | The partnership expands local access to oncology products while supporting the development of domestic pharmaceutical manufacturing capacity. |
Strategic Rationale | ADCAN gains access to a broader oncology portfolio and manufacturing know-how, while Pinnacle extends its products into the UAE market through a local partner. |
Potential Impact | Successful technology transfer could increase local production of oncology medicines and reduce dependence on imported supply. |
Key Takeaway | The agreement combines licensing of 12 oncology products with a structured programme to transfer manufacturing capability into the UAE. |
What to Watch | Completion of the technology-transfer stages, regulatory approvals and commencement of local manufacture. |
Primary Source | ADCAN Pharma |
Relevant Date | 3 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentários